CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Venlafaxine +1 moredrug
Likely dose
Venlafaxine 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04218123
NCT04218123Phase 3Completed

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

Medical University of South Carolina·interventional·Posted Jan 6, 2020·Updated Jul 23, 2024

In Brief

A Phase 3 clinical trial evaluating Venlafaxine and Placebo oral tablet for Meniere Disease. Completed, enrolled 40 participants across 1 site.

Detailed Summary

As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease. Venlafaxine is a safe and well-tolerated medication. It has never been trialed in Meniere's disease, but there is evidence that it could be effective in helping with vertigo attacks and other aspects of the disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeniere Disease
CountriesUnited States

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 6, 2020
Enrollment StartFeb 5, 2020
Primary CompletionSep 13, 2023
Study CompletionSep 14, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.5 years ago

Interventions

Venlafaxinedrug

Daily oral intake 37.5 mg

Placebo oral tabletdrug

Daily oral intake